The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Determinants Of Tissue- And Ligand-Specific Responses At The Mineralocorticoid Receptor
Funder
National Health and Medical Research Council
Funding Amount
$668,485.00
Summary
The steroid hormone aldosterone controls salt balance and hence, blood pressure. It also has been shown to have a significant role in cardiac failure. Although drugs that block the aldosterone receptor are beneficial in the treatment of heart failure, they are limited by potassium retention in the kidney. In order to develop tissue-specific blockers of the aldosterone receptor, it is necessary to identify mechanisms by which the receptor can be activated and/or blocked in specific tissues.
Cell Type Specific Mechanisms Of Mineralocorticoid Mediated Renal Injury In Glomerulonephritis And Diabetic Nephropathy
Funder
National Health and Medical Research Council
Funding Amount
$103,582.00
Summary
Mineralocorticoid exists normally in the human body to maintain fluid and salt balance. However, it is also implicated in diseases affecting the heart and the kidneys. My research aims to further our understanding on how mineralocorticoids contribute to kidney disease, and in particular, to investigate the role of specific kidney cells on mediating kidney injury. Ultimately this research may facilitate development of treatments allowing cell specific blockade of mineralocorticoids, which may red ....Mineralocorticoid exists normally in the human body to maintain fluid and salt balance. However, it is also implicated in diseases affecting the heart and the kidneys. My research aims to further our understanding on how mineralocorticoids contribute to kidney disease, and in particular, to investigate the role of specific kidney cells on mediating kidney injury. Ultimately this research may facilitate development of treatments allowing cell specific blockade of mineralocorticoids, which may reduce kidney diseases such as diabetic nephropathy.Read moreRead less
Cardiovascular disease is a leading cause of death in Australia, accounting for 36% of all deaths in 2004-05. Diseased blood vessels are its most common form, and the underlying process is atherosclerosis. Atherosclerosis is characterised by plaque formation in blood vessels. Plaque formation is problematic, and may lead to blood vessel blockage. We aim to identify novel targets that prevent plaque formation.
Mineralocorticoid Receptors - Mechanisms Of Ligand- And Tissue- Specific Activation
Funder
National Health and Medical Research Council
Funding Amount
$126,848.00
Summary
Heart disease is a major cause of death and economic burden in Australia and throughout the world. The steroid hormone aldosterone controls salt and water balance, blood pressure and has a significant role in heart failure. Although drugs that block the aldosterone receptor significantly help patients with heart failure, their use is limited by side effects. This work will identify the profile of proteins that promote aldosterone effects and enable the development of heart-specific blockers.
Novel Regulators Of Glucose Metabolism And Inflammation In Adipose Tissue Of Females
Funder
National Health and Medical Research Council
Funding Amount
$282,830.00
Summary
Obesity is a common problem which can lead to development of diabetes and heart disease. One of the major mechanisms by which obesity leads to these diseases involves a defect in the ability of insulin to stimulate uptake of glucose into cells. We have found that excess of the sex hormone testosterone in women can contribute to this defect in tissues. This study will investigate why testosterone causes this defect in females and whether this defect can be prevented using existing drug therapies.
Mineralocortioid Receptor-Mediated Injury In Progressive Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$707,008.00
Summary
Diabetes is the major cause of kidney failure. Activation of a hormone receptor (the mineralocorticoid receptor-MR) can promote kidney injury. Current drugs blocking MR can suppress diabetic kidney disease but are limited by their poor specificity and harmful side effects. Our study will help improve strategies for blocking MR by identifying the cell types responsible for MR-mediated injury and by examining whether a new class of drug targeting MR is a superior therapy to current MR inhibitors.
The steroid hormone aldosterone controls salt balance and hence, blood pressure. It also has been shown to have a significant role in cardiac failure. Although drugs that block the aldosterone receptor are beneficial in the treatment of heart failure, they are limited by potassium retention in the kidney. In order to develop tissue-specific blockers of the aldosterone receptor, it is necessary to identify mechanisms by which the receptor can be activated and/or blocked in these tissues.
Elucidation Of The Genetic Mechanisms Of Primary Aldosteronism: The Most Common, Curable Form Of Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$334,338.00
Summary
Hypertension is a major cardiovascular risk factor that affects 10-40% of the population. The steroid hormone aldosterone controls blood pressure and plays a significant role in hypertension. Primary Aldosteronism (PAL), a condition caused by the excessive production of aldosterone, is the most common, curable form of hypertension. I will identify the molecular mechanisms responsible for PAL, to advance the development of new diagnostic tools and identification of novel therapeutic targets.